Tessa Therapeutics is a technology company.
Tessa Therapeutics has raised $130.0M across 1 funding round.
Tessa Therapeutics has raised $130.0M in total across 1 funding round.
Tessa Therapeutics has raised $130.0M in total across 1 funding round.
Tessa Therapeutics's investors include Brandon Capital Partners, EQT Life Sciences, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Polaris Partners, Sanofi Ventures.
Tessa Therapeutics was a Singapore-based clinical-stage biotechnology company focused on developing next-generation cell therapies, including autologous and allogeneic CAR-T treatments, for hematological malignancies like lymphomas and solid tumors such as nasopharyngeal carcinoma and lung cancer.[1][2][3] It targeted unmet needs in cancer treatment by harnessing virus-specific T cells (VSTs) augmented with CD30-CAR, serving patients with relapsed or refractory conditions where traditional therapies fall short, with lead programs like TT11 (autologous) and TT11X (allogeneic "off-the-shelf") showing promising Phase 1/2 safety and efficacy data, including complete response rates up to 71.4% in Hodgkin lymphoma.[3][4] The company built a state-of-the-art manufacturing facility in Singapore and raised over $200M but ceased operations in June 2023 after failing to secure further funding or partnerships, dissolving without advancing to later-stage commercialization.[4]
Founded in Singapore, Tessa Therapeutics emerged as a biotech innovator leveraging virus-specific T-cell (VST) platforms to address cancers linked to Epstein-Barr virus, building a portfolio that expanded to autologous CAR-T like TT11 for CD30-positive lymphomas and allogeneic off-the-shelf therapies.[1][2][3] Key leadership included Thomas Willemsen as President and CEO from 2022, previously with Takeda, and Ivan Horak, M.D., as Chief Medical Officer and Chief Scientific Officer, driving a 2023 strategic pivot to prioritize allogeneic platforms amid resource constraints.[1] Pivotal early moments included 2017 partnerships with the Parker Institute for Cancer Immunotherapy and Vyriad, plus acquiring Euchloe Bio for checkpoint inhibitors, alongside FDA RMAT designation and EMA PRIME access for TT11, fueling clinical traction before funding challenges led to shutdown.[3][4][7]
Tessa stood out in the competitive CAR-T landscape through these key strengths:
Tessa rode the explosive growth of cell therapy during the 2010s-2020s CAR-T boom, capitalizing on timing when approved therapies like Kymriah validated the modality but highlighted needs for off-the-shelf options to cut costs and wait times.[1][3] Market forces like rising lymphoma incidence, EBV-linked cancers in Asia, and investor enthusiasm for immuno-oncology (pre-2022 downturn) favored its VST-CAR approach, influencing the ecosystem by advancing allogeneic tech and manufacturing in Singapore, a biotech hub.[2][4][6] Its dissolution underscores biotech funding risks amid clinical hurdles, yet data from TT11X contributed to industry learnings on durable allogeneic cells.[1][4]
Tessa's 2023 shutdown halted its promising pipeline, with assets like TT11X likely licensed or shelved, reflecting broader biotech volatility post-funding winter.[1][4] Looking ahead, trends in scalable allogeneic CAR-T—driven by manufacturing advances and combo therapies—could revive its tech via acquirers, potentially reshaping treatments for CD30+ cancers. Its legacy humanizes the high-stakes race in next-gen cell therapies, where early innovation meets commercialization realities, echoing the original promise of accessible, potent cancer killers.[3]
Tessa Therapeutics has raised $130.0M across 1 funding round. Most recently, it raised $130.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $130.0M Series A | Brandon Capital Partners, EQT Life Sciences, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Polaris Partners, Sanofi Ventures |